A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Richard Lafayette

Sean J. Barbour

Division of Nephrology, University of British Columbia, Vancouver, Canada

Robert M. Brenner

Vera Therapeutics, Brisbane, CA

Kirk N. Campbell

University of Pennsylvania Perelman School of Medicine, Philadelphia

Tom Doan

Vera Therapeutics, Brisbane, CA

Necmi Eren

Kocaeli University, Kocaeli, Turkey

Jürgen Floege

Departments of Nephrology and Cardiology, RWTH Aachen University Hospital, Aachen, Germany

Vivekanand Jha

George Institute for Global Health, UNSW, New Delhi, India

Beom Seok Kim

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Adrian Liew

Mount Elizabeth Novena Hospital, Singapore

Bart Maes

AZ Delta, Roeselare, Belgium

Atanu Pal

Department of Nephrology, Institute of Post Graduate Medical Education and Research, Kolkata, India

Roberto Pecoits-Filho

Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Richard K.S. Phoon

Faculty of Medicine and Health, University of Sydney, Sydney

Dana V. Rizk

University of Alabama at Birmingham, Birmingham

Hitoshi Suzuki

Department of Nephrology and Hypertension, Juntendo University Urayasu Hospital, Chiba, Japan

Vladimir Tesař

First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic

Hernán Trimarchi

Hospital Británico, Buenos Aires

Xuelian Wei

Vera Therapeutics, Brisbane, CA

Hong Zhang

Jonathan Barratt